Edison is focusing first on CoQ10 responsive mitochondrial diseases

Edison’s first drug, A0001, is entering clinical development in Q3, 2008

History More

In the 1960’s and 1970’s college science classrooms were clad with a map of the Biochemical Pathways. This compendium of thousands of enzymes and substrates and products was the culmination of over 5 decades of work. This included the identification of small organs within cells–...

[ Continue...]

Platform More

Edison’s focus is centered on the discovery and development of proprietary, effective and orally available CoQ10-based drugs that cross into the central nervous system for the treatment of CoQ10-responsive inherited mitochondrial and neurodegenerative diseases. CoQ10 is a...

[ Continue...]

Programs More

Edison’s target markets are mitochondrial diseases where CoQ10 or CoQ10 analogs have demonstrated evidence of efficacy, but where the response was suboptimal. Edison has segmented this market into two categories– adults with classic neurodegenerative diseases of aging such as...

[ Continue...]

FAQ More